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Abstract
Background: Glioblastomas are the most common primary brain tumour in adults. While the
prognosis for patients is poor, gene expression profiling has detected signatures that can sub-
classify GBMs relative to histopathology and clinical variables. One category of GBM defined by a
gene expression signature is termed ProNeural (PN), and has substantially longer patient survival
relative to other gene expression-based subtypes of GBMs. Age of onset is a major predictor of
the length of patient survival where younger patients survive longer than older patients. The reason
for this survival advantage has not been clear.
Methods: We collected 267 GBM CEL files and normalized them relative to other microarrays of
the same Affymetrix platform. 377 probesets on U133A and U133 Plus 2.0 arrays were used in a
gene voting strategy with 177 probesets of matching genes on older U95Av2 arrays. Kaplan-Meier
curves and Cox proportional hazard analyses were applied in distinguishing survival differences
between expression subtypes and age.
Results: This meta-analysis of published data in addition to new data confirms the existence of four
distinct GBM expression-signatures. Further, patients with PN subtype GBMs had longer survival,
as expected. However, the age of the patient at diagnosis is not predictive of survival time when
controlled for the PN subtype.
Conclusion: The survival benefit of younger age is nullified when patients are stratified by gene
expression group. Thus, the main cause of the age effect in GBMs is the more frequent occurrence
of PN GBMs in younger patients relative to older patients.
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Background
Glioblastoma Multiforme (GBM) persists as one of the
most lethal forms of human cancer with a median survival
of 12 to 14.6 months for patients who receive the latest
surgical, radiation, and chemotherapy treatment [1].
While increased efficacy of some chemotherapy drugs is
evident, the prognosis remains dismal [2]. Despite the
number of patients diagnosed with primary malignant
brain and central nervous system tumours is small (rela-
tive to other cancer types i.e. 1.35% of all primary malig-
nant cancers, U.S.), the morbidity and mortality of these
patients remains severe [3].
Gliomas are primarily identified by histological features
established by the grading scale of the World Health
Organization (WHO). Prominent features include necro-
sis, nuclear mitotic activity, vascular proliferation, and cel-
lular atypia [4]. In clinical oncology, the primary method
for identifying survival factors in high-grade gliomas has
been through Cox proportional hazards models. Covari-
ates such as histological classification, performance status,
and patient age at the time of surgery are particularly use-
ful to predict patient outcomes [5,6]. Numerous studies
have indicated that lower tumour WHO grade and
younger patient age are the most prominent indicators of
longer survival. Of patients diagnosed with a malignant
glioma, younger patients have a disproportionately higher
likelihood of being diagnosed with a lower grade glioma
relative to older patients. However, a frequently observed
phenomenon is that even among patients with the same
high grade of glioma, younger patients tend to have a
longer survival time. The reason for this survival advan-
tage has not been clear [7].
Our group in 2004 used a heterogeneous group of high-
grade gliomas that were categorized as WHO grade III and
grade IV to identify molecularly classifiable groups irre-
spective of histologic typing and correlated with survival
[8]. Despite this histological heterogeneity, these gliomas
could be successfully stratified into at least three molecu-
larly-defined glioma subgroups whose classification pre-
dicted patient survival. In particular, the HC1A tumours
were identified as a good survival group, which were cate-
gorized by the high expression of genes typically
expressed during neuronal development. The remaining
groups HC2A and HC2B were characterized by mitotic
and extra-cellular matrix related genes, respectively, and
both demonstrated poor survival prognoses. Recently, the
increased generation of whole genome microarray expres-
sion data has supported the gene expression signatures of
the three previously identified GBM subgroups and the
correlation with patient survival [9,10]. Phillips and col-
leagues suggested the following terms to be more descrip-
tive of the cellular characteristics: 'ProNeural' (PN) for
HC1A, 'Proliferative' (Pro) for HC2A, and 'Mesenchymal'
(Mes) for HC2B, which we adopt here [9].
In order to investigate the robustness and generality of the
gene expression-based groupings of GBMs, we have aggre-
gated the publicly available genome scale expression data
of histologically defined GBMs. Only samples performed
on the Affymetrix platforms were included for joint anal-
ysis and analytical simplicity. In total, 181 GBMs were
identified from the published literature for which Affyme-
trix microarrays were performed and CEL files were avail-
able. For many of these samples, survival and patient age
were available [8-13]. In order to have sufficient numbers
of samples to explore the correlation of expression signa-
tures with age in GBMs, we have also performed gene
expression analysis of an additional 86 GBMs in addition
to this publicly available dataset. From this combined
analysis, we demonstrate that about 86% of all tumour
biopsies classify strongly into one of the three molecular
subgroups as defined by the available gene list from Freije
et al., and for about 11%, there is strong evidence of a
novel group of GBMs that share expression features of Pro
and Mes subtypes from the bulk biopsy analysis. Further,
we investigated if there was a correlation between the
molecular subtypes in relation to age of the patient at time
of diagnosis and survival. We find that PN tumours are
substantially more commonly diagnosed in younger
patients, and that there is no survival advantage of age
independent of gene expression classification. In other
words, the beneficial effect of younger age in patients
diagnosed with GBM is entirely due to the observation
that for yet undefined reasons, younger adult patients
develop PN type GBMs more commonly than older
patients.
Results
Agglomeration of publicly available high-grade glioma 
microarray data confirms the presence of four molecularly 
distinct prognostic groups
In our previous work in characterizing and exploring
unrecognized subtypes of GBMs using genome-scale
expression analysis, our laboratory was able to develop
clear evidence of different gene expression signatures in
GBMs, and further demonstrated that the HC1A subtype
had prolonged patient survival relative to the HC2A and
HC2B types [8]. Several groups have now published large
gene expression analyses on GBMs that permit a more
robust meta-analysis and exploration of the genomic
landscape of GBMs. Through the efforts of several groups
and the sharing of raw microarray data, the dataset avail-
able for addressing questions of gene expression status of
individual genes and signatures has expanded to 267
glioblastomas (Table 1) and are organized and made
available as a unified dataset here. This larger scale data
permits exploration and testing of hypotheses generatedBMC Medical Genomics 2008, 1:52 http://www.biomedcentral.com/1755-8794/1/52
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in the initial microarray studies. We originally hypothe-
sized that there were at least three subtypes of molecu-
larly-distinct gliomas. With the accumulated genome-
scale gene expression data, we initially thought that addi-
tional gene expression signature subtypes would become
more evident. However, over 97% of our additional
tumour samples (from multiple institutions) continue to
bin clearly into one of the initially defined subtypes (Fig.
1A). A small set of tumours (11%) show evidence of a new
category which has expression features of both HC2A and
HC2B. The existence of the HC1A, HC2A and HC2B sub-
groups was corroborated by Phillips et al. independently
[9] and identified within previously published data [13].
The Phillips et al. group suggested descriptive names for
the gene expression signature based GBMs with HC1A
named ProNeural (PN), HC2A named Proliferative (Pro),
and HC2B named Mesenchymal (Mes). We indicate here
that a group of GBMs with both Pro and Mes gene expres-
sion signatures exists which we name "ProMes"(Figure
1A).
All of the microarray platforms can be used to identify the
PN, Pro, Mes and ProMes subgroups of GBMs. Thus, we
were able to merge data from the three most recent
Affymetrix genome-scale expression arrays for humans. In
terms of the gene voting compatibility between different
microarray platforms, we calculate that the percentages of
probesets which vote samples into their HC categories are
quite similar. For the PN samples an average of 52%, 54%,
and 47% of the PN probesets vote these tumours as PN
across the U95Av2, U133A, and U133 Plus.2.0 arrays,
respectively. The Pro samples also vote with an average of
Table 1: Combined Data Sources
Studies No. GBM IV Set Array PMID GEO Accession HC Class Distribution
Freije et al. [8] 46 0 U133A 15374961 GSE4412 PN (19/46)
Pro (11/46)
ProMes (2/46)
Mes (14/46)
Phillips et al. [9] 55 2,3 U133A 16530701 GSE4271 PN (18/55)
Pro (19/55)
ProMes (4/55)
Mes (14/55)
Rich et al. [10] 31 4 U133A 15899794 NA PN (2/31)
Pro (6/31)
ProMes (8/31)
Mes (15/31)
Mischel et al. [11] 2 7 U95Av2 12700671 NA PN (1/2)
Pro (1/2)
ProMes (0/2)
Mes (0/2)
Shai et al. [12] 19 8 U95Av2 12894235 NA PN (3/19)
Pro (2/19)
ProMes (4/19)
Mes (10/19)
Nutt et al. [13] 28 6 U95Av2 12670911 NA PN (10/28)
Pro (7/28)
ProMes (2/28)
Mes (9/28)
UCLA New 28 1 U133A New New PN (11/28)
Pro (3/28)
ProMes (1/28)
Mes (13/28)
UCLA New 27 1 U133 2.0 New New PN (7/27)
Pro (3/27)
ProMes (5/27)
Mes (12/27)
Barrow New 31 5 U133A New New PN (6/31)
Pro (9/31)
ProMes (3/31)
Mes (13/31)
Total 267BMC Medical Genomics 2008, 1:52 http://www.biomedcentral.com/1755-8794/1/52
Page 4 of 12
(page number not for citation purposes)
72%, 69%, and 92% of the Pro probesets contributing to
the positive votes among the three arrays. The ProMes cat-
egory was identifiable from data from each of the three
platforms with an average of 58% and 43% (Pro and Mes
probesets, respectively), 64% and 45%, and 85% (only n
= 3 U133 Plus 2.0 "Pro" samples) and 55% of their
probesets. Finally, Mes samples vote with an average of
57%, 62%, and 51% of the Mes probesets on all three
array types. Each sample voted over 47% of its category's
probesets when voting into its respective HC class. Thus,
even though differing sets of probes were used to identify
the subgroups from the array platforms, the groups them-
selves were reliably identified.
The patient survival durations of each gene expression
group confirms the prognostic utility of the gene signa-
ture-based predictor (Fig. 1B). PN GBM patients (n = 77)
have a mean survival of 2.16 years (median = 1.4 years)
while Pro (n = 61), Mes (n = 100), and ProMes (n = 29)
GBM patients have a mean survival of 1.05 years (median
= 283 days), 1.20 years (median = 322 days), and 1.44
years (median = 385 days), respectively. Moreover, only
35% of PN patients survive less than 1 year from the date
of surgical resection, while about 60% of Pro, 49% of
ProMes, and 58% of Mes patients succumb to their malig-
nancies within the first year after resection. Part of the rea-
son for the low survival is likely due to the lack of
homogenous treatment across institutions over a period
of several years. However, we note that among patients
who received current standard of care (e.g. combined high
dose radiotherapy, aggressive surgery, and Temozolomide
(N = 36)), only 44% of these patients were alive at 12
months post diagnosis and only 39% (n = 14/36) survive
up to or beyond 14.6 months. Thus, differences in thera-
peutic efficacy from the various studies included here are
unlikely to alter the fundamental conclusions and that
Gene expression-based profiles related to survival duration across GBM tumours Figure 1
Gene expression-based profiles related to survival duration across GBM tumours. A. 377 probesets were used to 
classify the GBMs available on the U133A and U133 Plus 2.0 arrays, while 177 probesets were used to classify the tumours 
available on the U95Av2 arrays. The four glioblastoma types: PN: ProNeural (yellow, n = 77), Pro: Proliferative (blue, n = 61), 
ProMes: Proliferative-Mesenchymal (purple n = 29), and Mes: Mesenchymal (red, n = 100). B. Percent composition of Long 
(LTS), Medium (MTS), and Short (STS) term survival across the three glioma gene-signature tumour types. Over one-third of 
PN-classified tumour patients survive over 2 years, while over half of Pro, ProMes, and Mes classified tumour patients succumb 
in less than 1 year.BMC Medical Genomics 2008, 1:52 http://www.biomedcentral.com/1755-8794/1/52
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therapy is a minor contributor to the effects measured in
terms of patient survival. The findings from this expanded
dataset firmly corroborate the importance of gene signa-
ture based classification in categorizing glioblastomas
into prognostically meaningful molecular groups. While
there is little difference in survival between Pro, Mes, and
ProMes tumour carriers, all have dramatically shorter
patient survival times than the PN GBM patients. For the
subset of the patients where treatment data were available,
there were no differences in treatments attempted in the
classification groups to account for the difference in sur-
vival length of the patients.
Molecular Classification & Age Analysis
For adult patients who are diagnosed with GBM, younger
age at diagnosis is a strong predictor of longer patient sur-
vival. The mechanism for this observation has not been
clear, and in the study by Freije et al., age and PN tumour
type were clearly correlated [8]. With the larger group of
patients and GBM tumour biopsies available from the
published work of several groups and new data reported
here, we explore the relationship between the age of the
patient, survival, and gene expression signature-based
subtype of GBM. We sought to determine the relative
importance of the PN subtype as compared to age of the
patient. For these analyses, 28 GBM samples were
removed from the analysis as no available age data were
provided from the published data.
In accordance with previous analyses, patients with PN
GBMs (n = 77) have substantially longer survival than
patients with non-PN GBMs (Pro, Mes, or ProMes) (n =
190) (P-value = 4.9e-6) (Fig. 2A). Patients with PN GBMs
have an average survival of 2.2 years (median = 1.4 years)
while the patients with non-PN GBMs survive on average
1.2 years (median = 0.9 years). We demonstrate that virtu-
ally all of the age effect observed in GBM patients is due to
the increased likelihood of being diagnosed with the PN
subtype in patients younger than 40. First, patients were
partitioned by age to determine if our dataset has the com-
monly observed beneficial young age affect. As expected,
patients younger than 40 years (n = 32) suffering from
Kaplan-Meier analysis of GBM patient survival according to predictive gene expression signatures and age alone Figure 2
Kaplan-Meier analysis of GBM patient survival according to predictive gene expression signatures and age 
alone. A. PN GBM patients vs. non-PN GBM patients. Molecularly categorized GBM patient survival comparison shows PN 
GBMs survive longer than non-PN GBMs (Pro, Mes, and ProMes). PN GBM patient survival (mean = 2.2 years, median = 1.4 
years) vs. non-PN GBM patient survival (mean = 1.2 years, median = 0.9 years). B. GBM patient age difference for survival: 
younger than age 40 vs. older than age 40. GBM patients younger than age 40 survive longer than GBM patients older than age 
40. GBM age < 40 patient survival (mean = 2.1 years, median = 1.3 years) vs. GBM age > 40 patient survival (mean = 1.4 years, 
median = 0.9 years).BMC Medical Genomics 2008, 1:52 http://www.biomedcentral.com/1755-8794/1/52
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GBMs survived longer than those over 40 years of age (n
= 207) by about two-fold duration (P-value = 0.044) (Fig.
2B). Patients diagnosed younger than age 40 survived on
average 2.1 years (median = 1.3 years), and patients over
age 40 survived on average 1.4 years (median = 0.9 years).
Next, we stratified the patients based on the subtype of
GBM. For the patients diagnosed with non-PN GBMs
(Pro, Mes, and ProMes), there was no significant differ-
ence in survival between younger patients (n = 17) and
older patients (n = 155) (P-value = 0.64) (Fig. 3). Thus,
when the tumour type was controlled by gene expression-
based molecular type, there was no detectable beneficial
effect of younger age. When patients were stratified based
on age for all of the patients with PN subtypes, age was
not a substantial predictor of survival (P-value = 0.09,
data not shown). If we ask whether gene expression based
classification is a patient survival predictor within the dif-
ferent age groups, PN GBM subtype remains a strong pre-
dictor of longer patient survival. Of patients under 40
years of age at diagnosis, those diagnosed with PN GBMs
(n = 15) demonstrate a significantly longer survival dura-
tion than those similarly young patients who were diag-
nosed with non-PN GBMs (n = 17) (P-value = 0.011) (Fig.
4A). Similarly, the beneficial gene expression based classi-
fier was detected in the older group of patients. Patients
diagnosed at over the age of 40 with PN GBMs (n = 52)
survived significantly longer than age-matched patients
over the age of 40 that suffered from non-PN GBMs (n =
155) (P-value = 0.0052) (Fig. 4B). Combined, these data
indicate that the predominant cause of the beneficial age
affect observed in GBM patients is due to the proportion-
ally higher likelihood of patients younger than 40 to be
diagnosed with the PN type GBM relative to the Pro, Mes
or ProMes types. In our sample set of the patients younger
than 40 years of age, 47% (15/32) were PN, while only
25% (52/207) of the patients older than 40 years of age
were diagnosed with PN type GBMs (Fishers exact p value
= 0.011). GBMs increase in frequency with older age, and
of those patients in our dataset over age 60, 23% have the
PN type, which indicates a decreasing chance of develop-
ing this subtype of GBM with advancing age.
Multivariate and Univariate Cox proportional hazards 
analyses support that the molecular signature status of 
GBMs demonstrates greater hazard prediction than age
To measure the robustness of the PN and non-PN molec-
ular classifier amongst several additional covariates, mul-
tivariate and univariate Cox proportional hazards
analyses were performed across the GBM patients where
age data were available (N = 239: PN (n = 67), non-PN (n
= 172) Tables 2 and 3). The model tested the following
covariates: age, glioma gene signature, and expression sta-
tus of MGMT, VEGF, and EGFR. MGMT, VEGF, and EGFR
were added in as individual expression covariates due to
prior reports of their possible individual contributions in
relation to survival prediction [14,15]. Our analysis indi-
cated that only increased VEGF expression significantly
correlated with increasing age (data not shown), while
MGMT and EGFR expression levels did not show signifi-
cant correlations with age. While univariate analysis dem-
onstrated as expected that the 'Age 40 and above' covariate
represents a near significant marker for hazard (HR = 1.44,
P-value = 0.067), age was not a significant survival predic-
tor in the context of multivariate analysis (HR = 1.20, P-
value = 0.39). Within the univariate model, the non-PN
classification demonstrates a high hazard ratio (Table 3:
HR = 1.94, P-value = 3.15e-5). Within the multivariate
model, the most significant hazard covariate for patient
outcome was in fact the non-PN molecular subtype (Table
2: HR = 1.93, P-value = 1.4e-4).
Finally, several molecular studies have demonstrated that
the aberrant expression of certain genes serve as useful
prognostic indicators for patient survival. When the
expression status of MGMT, VEGF, and EGFR were com-
pared in the multivariate analysis with our molecular clas-
sifier, only MGMT expression demonstrated significant
performance in the predictive models (Multivariate HR =
1.46, P-value = 6.6e-3). The higher expression of MGMT
associated with poorer survival is consistent with other
studies that report the expression of MGMT silenced by
promoter hypermethylation enhances GBM patient sur-
vival [16]. MGMT silencing may also be responsible for
conferring additional survival benefit when comple-
mented by Temozolomide treatment, but this could not
be studied in the current analysis [17]. In addition to
MGMT, VEGF and EGFR expression levels were studied for
possible relationships to poor survival outcomes as indi-
cators of angiogenesis and constitutive signal transduc-
tion, respectively. However, from the multivariate results
neither VEGF nor EGFR 'activation', as determined by the
expression arrays, contributed significantly to hazard
(VEGF HR = 1.20, P-value = 0.33; EGFR HR = 0.86, P-
value = 0.30). Interestingly, with respect to univariate
models, one published univariate Cox proportional haz-
ards study reported that VEGF expression was a significant
prognostic indicator for poor survival, while EGFR expres-
sion was not [15]. Our univariate analysis confirmed this
finding as VEGF expression in the univariate model was
the only gene whose expression indicated statistically sig-
nificant hazard amongst these three genes (HR = 1.35, P-
value = 0.028), and EGFR failed to display significant haz-
ard implications in both multivariate and univariate mod-
els (Univariate HR = 0.91, P-value = 0.51). These weaker
effects from individual gene analyses are likely due to
their partial contribution to the overall expression signa-
tures. VEGF is part of the ProMes and Mes expression sig-
natures while EGFR is part of the PN, Pro, and ProMes
expression signatures. These data may highlight the com-
plex nature of genetic effects within GBMs which are notBMC Medical Genomics 2008, 1:52 http://www.biomedcentral.com/1755-8794/1/52
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derived from a single gene but rather a complex repro-
gramming of hundreds of genes being dysregulated. Thus,
the relative contribution of individual, but important,
genes is less than the aggregate set defined by the whole
gene expression profile. The multivariate analysis sup-
ports this conclusion as the ProNeural versus non-ProNe-
ural subtype of GBM within patients demonstrates itself as
the primary favourable survival prognosis indicator.
Discussion
This study uses available genome-scale gene expression
based analyses across glioblastomas to further investigate
observed age effects in patient survival and creates a uni-
fied dataset for further exploration of gene expression cor-
relates in glioblastomas. We add to the literature 86
additional GBM biopsy gene expression profiles per-
formed on the U133A and U133 Plus 2.0 platforms. We
confirm that within histologically defined GBMs, there
are robust and repeatedly observed gene expression signa-
ture based groups of GBMs, which produces a classifica-
tion scheme within GBMs. Within this aggregate dataset
of 267 GBMs, the three previously defined molecular gli-
oma subgroups were robustly detected as defined by over-
expression of a series of related genes: Neurogenesis/
HC1A (a.k.a. ProNeural), Mitotic/HC2A (a.k.a. Prolifera-
tive), and Extra-Cellular Matrix related/HC2B (a.k.a. Mes-
enchymal). From the larger dataset, we observe evidence
of a new subtype that highly co-expresses genes in both
the Pro and Mes groups, which we term "ProMes". Of
these four molecularly distinct groups identified, only PN
portends a favourable prognosis relative to the other
expression based groups.
Kaplan-Meier analysis of GBM patient survival for Pro, Mes, and ProMes GBM patients according to age Figure 3
Kaplan-Meier analysis of GBM patient survival for Pro, Mes, and ProMes GBM patients according to age. GBM 
patients suffering from Pro, Mes, and ProMes tumours do not survive any better if younger than age 40 than identically gene 
expression-classified GBM patients older than the age of 40.BMC Medical Genomics 2008, 1:52 http://www.biomedcentral.com/1755-8794/1/52
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In this study, we determine that the reason that younger
patients diagnosed with GBMs have longer survival dura-
tions than older GBM patients is due to the observation
that younger patients tend to develop the favourable PN
GBM type more commonly relative to older patients. The
reason for this observed age effect is not clear at this time,
but may have to do with the precursor cell that develops
into GBMs changing over time. One could hypothesize
that the precursor cell that gives rise to the PN type dimin-
ishes in abundance in the CNS with advancing age. How-
ever, given that GBM incidence increases greatly with age,
the absolute numbers of PN GBMs is actually numerically
higher in older patient groups. Thus, we favour a model
that the precursor cell type that gives rise to the Pro and
Mes types of GBMs are increasingly likely to become neo-
plastic over time while this effect is not as pronounced
within the PN type precursors.
PN type GBMs represent a unique tumour aetiology
whose idiopathic molecular mechanisms manifest in sur-
vival periods spanning from two to ten years in contrast to
ten to fifteen months for the Pro, Mes and ProMes types
of GBMs. Historically, the percentage of GBM patients
who demonstrate long term survival of 3 years or more
has been reported to be approximately 5% [18]. This 5%
incidence rate matches well with the observations
Kaplan-Meier analysis of GBM patient survival partitioned by age and predictive expression signature Figure 4
Kaplan-Meier analysis of GBM patient survival partitioned by age and predictive expression signature. A. GBM 
patients younger than age 40 partitioned by PN status versus non-PN status. Younger patients with PN GBMs survive longer 
than fellow younger patients with non-PN GBMs. PN GBM patients age < 40 survival (mean = 3.0 years, median = 2.9 years) vs. 
non-PN GBM patients age < 40 survival (mean = 1.4 years, median = 0.8 years). B. GBM patients older than age 40 partitioned 
by PN status versus non-PN status. Older patients with PN GBMs survive longer than fellow older patients with non-PN 
GBMs. PN GBM patients age > 40 survival (mean = 1.9 years, median = 1.1 years) vs. non-PN GBM patients age > 40 survival 
(mean = 1.2 years, median = 0.9 years).
Table 2: Multivariate Cox Proportional Hazards Ratio: Five 
Covariates
Model Covariates Covariate Hazard Ratio 95% CI P-value
AGE >= 40 1.20 0.80 – 1.80 0.39
PN status non-PN 1.93 1.38 – 2.70 1.4e-4
MGMT ON 1.46 1.11 – 1.92 6.6e-3
VEGF ON 1.20 0.87 – 1.53 0.33
EGFR ON 0.86 0.64 – 1.15 0.30
Table 3: Univariate Cox Proportional Hazards Ratio: Five 
Covariates
Model Covariates Covariate Hazard Ratio 95% CI P-value
AGE >= 40 1.44 0.97 – 2.14 0.067
PN status non-PN 1.94 1.42 – 2.66 3.1e-5
MGMT ON 1.27 0.97 – 1.66 0.078
VEGF ON 1.35 1.03 – 1.76 0.028
EGFR ON 0.91 0.68 – 1.21 0.51BMC Medical Genomics 2008, 1:52 http://www.biomedcentral.com/1755-8794/1/52
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reported here in which 8% (18/267) of our PN GBM
patients are observed to survive 3 years or longer. The
identification of the PN subgroup is important for patient
management and stratification into small phase II clinical
trials for experimental therapeutics as uneven representa-
tion of the PN GBM diagnoses would greatly alter
observed survival times irrespective of potentially active
agents [19]. The identification of the gene expression sub-
type is clearly more important for patient stratification
within clinical trials than age.
It is likely that the use of genome-wide expression based
molecular classification will result in less variation in
tumour diagnoses and provide more specific guidance to
clinicians. The agglomeration of gene expression datasets
permits meta-analyses that were insufficiently powered in
multiple individual publications. Resources for the shar-
ing of genome-scale expression datasets have been set up
at Array Express, Gene Expression Omnibus, and Celsius
[20,21]. Critical to the sharing of microarray data is pro-
viding raw microarray data as opposed to processed data.
In order to facilitate this sharing, the NIH Neuroscience
Microarray Consortium has established Celsius, which is
a community resource of CEL (image) files performed on
the Affymetrix platform for public distribution using pro-
grammatic tools. At the writing of this manuscript, the
Celsius database contains CEL files from human experi-
ments performed on U95Av2 arrays (n = 5 006), U133A
arrays (n = 13 818), and U133 Plus 2.0 arrays (n = 10
376). To fully capture and leverage the value of microarray
expression data, a greater commitment must be made to
capture and share clinical covariates and raw expression
data. For instance, in this study of 267 glioblastomas, a
total of 433 GBM CEL files were initially identified across
the U95Av2, U133A, and U133 Plus 2.0 platforms. Of
these, thirty-six percent (160/433) were immediately
removed from this study due to a lack of any clinical data.
Additionally, not all microarray CEL files or their matched
clinical data points are systematically retrievable.
Amongst the samples gathered at UCLA, we simultane-
ously gathered additional covariates such as extent of sur-
gical resection, Karnofsky Performance Scores (KPS),
lesion locations, and MRI scans. We have begun to make
all of these data available through a web interface in order
to promote data sharing and exploration of gene expres-
sion differences in gliomas. All of the data added here are
deposited in Gene Expression Omnibus (GEO), and can
be explored at our real-time survival-synchronized search
engine "Probeset Analyzer" [22].
Clinical Decision Impact and Improved Public Disclosure
In large academic hospitals, tumours come from a wide
variety of patients from across different cities, states, or
countries. In contrast, local hospitals treat their regional
constituencies. The potential for demographically-biased
patient populations and biased tumour subsets is a possi-
bility. These trends can reinforce particular treatment
strategies at local institutions over time. For example, if
patients from a community highly populated by retirees
(e.g. southern Florida) presented with a GBM, clinicians
would be apt to predict that these older patients would
likely succumb to their malignancies within one year.
Current treatment for patients diagnosed with high grade
gliomas consists of surgical resection followed by toxic
and expensive therapy schedules that are minimally effec-
tive. But if these elderly patients were suffering from a PN
tumour, they would have a high likelihood for surviving
at least two to three years or longer. These patients could
then be distinguished from patients who otherwise
present identically under the microscope or according to
their patient biographical sketch. This would permit time
to enrol in potentially beneficial clinical trials. Thus, if
grade and age alone were considered for prognosis, these
factors would lead clinicians to prescribe unnecessary
treatments due to trends reinforced by regional sampling
biases.
Conclusion
We provide an explanation for why younger patients diag-
nosed with GBM have longer life expectancies than older
patients using accumulated whole-genome microarray
expression data and clinical variables. We have discovered
the reason that younger patients tend to survive longer is
because they are more likely to present with PN gene sig-
nature tumours relative to the more common and aggres-
sive Pro, Mes, and ProMes GBM types. The PN molecular
classification predicts an enhanced survival performance
by at least two to ten years irrespective of age when tested
against age-matched, Pro, Mes, or ProMes molecularly-
classified tumours. The application of Cox proportional
hazards studies have also confirmed that having a non-PN
tumour was the most statistically significant factor in pre-
dicting precipitous short survival over age by two orders of
magnitude. These data lend more evidence to the clinical
reality that high-grade gliomas can be molecularly distinct
tumours. Therefore, different tumours with distinct aetiol-
ogies should be differentially segregated in terms of their
treatment regimens and especially their clinical trial
assignments. The benefits for clinicians would be a reduc-
tion in the heterogeneous admixture of genetic back-
ground for treatment cohorts and a potential reduction in
the percentage of non-responders for molecularly-tar-
geted investigational new drugs. Patients accurately classi-
fied and characterized for the biology of their tumour may
potentially benefit from a variety of molecularly-targeted
treatments as the inclusion criteria for clinical trials
become simultaneously based on molecular signatures.BMC Medical Genomics 2008, 1:52 http://www.biomedcentral.com/1755-8794/1/52
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Methods
Microarray and Clinical Data Collection
Clinical data including histopathology, age, sex, and sur-
vival time from diagnosis were retrieved from 181 gliob-
lastomas which have been reported within previous
studies between 2003 and 2006 (Table 1) and for which
CEL files (Affymetrix, Santa Clara, CA) were available
from the authors. In addition, we collected 86 new
patient-unique tumour biopsies from the UCLA Neuro-
oncology Program (n = 55) and the Barrow Neurological
Institute (n = 31) for a grand total of 267 glioblastomas.
Newly acquired tumours were collected through institu-
tional review board approved protocols and assigned
WHO grades at UCLA Neuropathology or Barrow Neu-
ropathology by PSM. Time of survival (days), sex, and, age
were collected where available [see Additional file 1].
Patient age at the time of diagnosis was available for 239
patients and ranged from 18 to 86 years. Sex of the indi-
vidual was available for those 239 patients (151 males
and 88 females).
Microarray Experimentation
Total RNA was purified from fresh frozen tumour biopsies
and visually inspected for tumour content using Qiagen
RNAeasy columns and standard manufacturer's protocols.
Labelled one round cRNA was generated using kits (Gene-
Chip One-Cycle Target Labelling and Control Reagent)
from Affymetrix. cRNA was quantified and 15 micrograms
were hybridized to U133A and U133 Plus 2.0 arrays at the
UCLA DNA Microarray Facility using standard protocols
recommended by the manufacturer [see Additional file 2].
All newly generated CEL files were deposited into the Cel-
sius microarray database and this system was used to nor-
malize relative to other microarrays of the same
Affymetrix platform using RMA with default settings from
the Bioconductor R library [20,21,23,24].
Combination of microarray data
The Celsius microarray database, which houses over 20
000 human CEL files on various array iterations, was used
to quantify and normalize the three microarray platform
datasets with comparison groups of 50 random samples
selected from each respective platform for RMA normali-
zation and quantification using default parameters. Only
probesets from the U133A portion of the Freije et al. paper
that are retained or map to the same gene were analyzed
from each tumour type. All microarray CEL files analyzed
in this study in conjunction with their clinical covariates
are accessible from the Gene Expression Omnibus (GEO)
(Series Accession number: GSE13041).
Sample membership by HC Classification Gene Voting
The Hierarchical Clustering (HC) classification for each
glioma was determined by the gene voting strategy as
described previously [8]. Briefly, the mean value of each
probeset was evaluated from all samples within each of
the three microarray platforms U95Av2, U133A, and
U133 Plus 2.0 separately. Second, the probesets from each
sample were assigned "yes" or "no" votes if that probeset's
value was above or below the aforementioned probeset
mean of its platform. Third, the "yes" or "no" votes of
each probeset from the 377 probesets contained within
the U133A portion of the 595 HC probeset classifier
(which was based on U133A and U133B data) were tal-
lied and used to categorize every glioma into one of three
HC molecular groups. All of the 377 probesets from the
377 used for classification were on the U133A and the
U133 Plus 2.0 array types, and 177 of the probesets were
able to be matched to the same genes from the older
U95Av2 arrays. For probesets that were unavailable on the
U95Av2 arrays, the mean value of the probesets on the
U133A and U133 Plus 2.0 arrays were calculated and
intercalated for the missing row values of the U95Av2
samples strictly for visualization purposes and not gene
voting. Lastly, each tumour was voted into one of three
HC groups based on the highest vote tally: 1A vote = (tally
of 1A probesets above the mean)/(total 1A probesets); 2A
vote = (tally of 2A probesets above the mean)/(total 2A
probesets); 2B vote = (tally of 2B probesets above the
mean)/(total 2B probesets). A few gliomas appeared to
vote almost equally well into both the 2A and 2B catego-
ries and are defined as "2A2B", which is defined where the
highest vote category must be a 2A or 2B and the second
highest vote must be 2B or 2A, respectively with at least a
33% vote. The lists of probesets used for voting each
tumour across each of the Affymetrix platforms is availa-
ble [see Additional file 3].
Kaplan-Meier and Cox Regression Analysis
Kaplan-Meier survival plots and Cox proportional hazard
regression analyses were implemented in R version 2.5.0
using the "survival" library. Survival data and vital status
for UCLA samples were based on time in days elapsed
from surgical resection to the date of death up to May 1,
2006. The full R code is available and documented [see
Additional file 4].
MGMT, VEGFA, EGFR Expression State Determination
Expression states for the MGMT, VEGFA and EGFR
probesets were called "ON" or "OFF" based on whether
their probesets' expression levels were above or below
their respective mean within each platform. The probesets
employed for the genes from each platform are listed [see
Additional file 3].
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